0.96 USD
▲-0.06+5.17%
盘后 0.92 +0.55%
2026-08-03
市值
$179.55M
市盈率
—
EPS
-1.08
股息率
—
52 周区间
0.16 – 3.39
成交量
14.49M
Beta
0.80
目标价
5.40
52W 低 0.1652W 高 3.39
价格走势
公司简介
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, ...